John T. Kilcoyne
Chief Executive Officer and President
John Kilcoyne brings more than 33 years of experience in the medical device market to RVO®. He has a proven record in understanding the needs of both patients and doctors combined with an ability to move companies from development into the commercial market.
Most recently, he served as Chairman and CEO of Micrus Endovascular Corporation, until its sale to Johnson & Johnson in September 2010. Mr. Kilcoyne also previously served as President and Chief Executive Officer of Solace Therapeutics, a medical device company from 2002 to 2004. Prior to Solace, he served as the President and Chief Executive Officer of Endonetics, Inc. from 1997 until its acquisition by Medtronic in December 2001.
Mr. Kilcoyne received his B.S. from Cornell University.
Louis Bunn
Chief Financial Officer
Louis Bunn has over 20 years experience as a senior financial executive with development-stage medical device companies. He was instrumental in raising over $150 million in venture equity and debt, as well as being actively involved in developing and implementing strategies for growth and maximizing shareholder value.
Most recently, Mr. Bunn was Chief Financial Officer and Senior Vice President of Finance & Administration of 3F Therapeutics, Inc., a company that focused on tissue heart-valve products. 3F Therapeutics, Inc. was acquired by ATS Medical, Inc. in September 2006. Previously, Mr. Bunn was Chief Financial Officer and General Manager of EndiCOR Medical, Inc., a company specializing in coronary catheter products. The company was acquired by Ev3, Inc. in 2002. Prior to EndiCOR, Mr. Bunn served as Vice President and Chief Financial Officer of SenDx Medical, Inc., a critical care diagnostic equipment company, which was acquired by Radiometer in 1998.
Mr. Bunn is a certified public accountant (inactive) and has a BA in Business Administration from San Diego State University.
Lynne Archer
VP of Clinical Affairs
Lynne Archer has over 25 years experience in the field of clinical research. For the past 17 years, Ms. Archer has been exclusively involved in ophthalmic clinical research. Most recently, as Vice President of Clinical Science at Eyeonics, she was responsible for developing and implementing the clinical strategy and was instrumental in obtaining the first and only FDA-approved accommodating IOL.
Prior to Eyeonics, Ms. Archer was the Ophthalmic National Study Director for Pharmacia. While at Pharmacia, Ms. Archer was active in the approval of the first FDA prostaglandin drug, Xalatan, for the treatment of glaucoma.
Joe Collins
Vice President of Operations
Joe Collins brings 32 years of contact and intraocular lens manufacturing experience to the ReVision team. His experience in process engineering, Class III regulatory environment devices, advanced automation systems; lens design and manufacturing have prepared him with the management and technical skills which will serve him well in his new role at ReVision Optics.
Most recently, Mr. Collins was Co-Founder and Vice President of Manufacturing and R&D at SynergEyes. Mr. Collins previously served as the first Process Engineer for the premium CSI contact lens brand as well as a project leader on successful manufacturing automation systems at Wesley Jessen. Prior to Wesley Jensen, he held various operations and manufacturing roles at Syntex Ophthalmics, Sola, Pilkington Barnes Hind and Ciba Vision. As a respected industry veteran, Mr. Collins has also provided consulting for Allergan Inc, and Addition Technology, Inc.
Nick J. Manesis, Ph.D.
Vice President, Research & Development
Nick Manesis has 30 years of experience in materials science and engineering. Mr. Manesis has been involved with development of class II and III medical devices across several product areas including ophthalmic implants, contact lenses, spinal injectables, breast implants, dermal fillers, bariatric devices, and improved tissue integration of implants. He has extensive experience with both synthetic and natural biomaterials for biomedical applications. Most recently, Mr. Manesis served as Vice President of Business Development promoting tissue integration technology at Solaris Technology Group in San Diego. He has also held lead positions within Allergan and CooperVision, having been instrumental in setting up materials and analytical functions. Mr. Manesis worked for Hewlett-Packard Company and was also involved in development of media products during the early days of large format inkjet printing. He holds a doctorate degree in Chemistry from the University of California, San Diego and Bachelor of Science degrees in Chemistry and Biology from the University of Wisconsin, Eau Claire.
Frank Shields
Vice President, Worldwide Sales
Frank Shields has over 25 years of surgical sales and marketing experience that encompasses the development, launch and growth of several innovative cataract and refractive surgical devices in the field of ophthalmology.
Most recently, Mr. Shields was Regional Sales Manager at Bausch & Lomb Surgical where he successfully launched and grew the Microsurgical Cataract Segment (MICS), the Premium Accomodative IOL Segment as well as the Femtosecond Cataract Laser market. These successful launches helped Mr. Shields attain the highest market share division within the company and induction into the Bausch and Lomb “Hall of Fame”.
Prior to Bausch & Lomb, Mr. Shields helped launch the first commercial Microkeratome at Chiron vision which helped introduce LASIK into the United States. At IOLAB, a Johnson & Johnson company, Mr. Shields launched some of the first foldable IOL’s which helped pave the way for topical, clear corneal cataract surgery.
Mr. Shields holds a B.S. In Advertising and Business from the University of Florida.
Luis G. Vargas, M.D.
Vice President of Medical Affairs/Medical Director
Luis Vargas joined RVO® in January 2013 and has over 10 years of experience in the medical device industry, with a proven track record in defining Medical Affairs strategy, direction, planning and execution, from early translational development activities to mature product life cycle management. Dr. Vargas is a physician-ophthalmologist from Universidad Javeriana in Bogota, Colombia with fellowships at the Medical University of South Carolina in the USA and Ruprecht Karls University of Heidelberg in Germany.
Prior to RVO, Luis was the Vice President of Medical Affairs and Medical Director at Visiogen, Inc., which was acquired by Abbott Medical Optics. At Abbott, Dr. Vargas served as Associate Medical Director, Medical Affairs.
Dr. Vargas has published over 35 peer-reviewed papers and delivered over 100 presentations at scientific conferences worldwide.
Sarah Cannon
Vice President of Global Marketing
Sarah Cannon has more than 12 years of focused ophthalmic industry experience. Her development and execution of brand strategy and positioning to both the professional and patient has helped her drive brand growth and creation of premium markets.
Prior to working for RVO, she spent most her career at Alcon Labs in both the pharmaceutical and surgical divisions. After earning the prestigious Alcon President’s Club award during her tenure in sales, she was promoted into surgical marketing group primarily in the premium intraocular lens business segment. Through these capacities, she gained extensive product and direct-to-consumer experience and focused on both the ophthalmic and optometric markets.
Ms. Cannon received her B.S. from Texas A&M University and earned her M.B.A. from Texas Christian University.
Tonya Porter
VP of Global Regulatory Affairs & Quality Assurance
Tonya Porter has been a member of the RVO team since 2006 and an integral member of the Regulatory team since 2014. In her new role as Vice President of Global Regulatory Affairs & Quality Assurance, she is responsible for US product approvals, international product registrations, and assuring the highest quality of products are provided to the RVO customer. Ms. Porter is one of the longest tenured employees at RVO and has a diverse background of experience from product development to managing international clinical trials.
Prior to joining RVO, she served at the US Food and Drug Administration (FDA).
Ms. Porter earned her BS degree in Engineering from the Harvey Mudd College, and an MS in Biomedical Engineering from the University of California, Irvine.
